Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-Term Follow-up of Subjects Who Were Treated With ST-920
Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT05039866

Active Not RecruitingN/A

Sponsor: Sangamo Therapeutics

Conditions: Fabry Disease, Fabry Disease, Cardiac Variant

Interventions: ST-920

Countries: United States, Australia, Canada, Germany, United Kingdom

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Subjects who received ST-920 therapy in a separate parent trial
* Subjects who have consented to participate in this LTFU study.

Exclusion Criteria:

-This study has no exclusion criteria
Locations (13)
  • Irvine, California, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Iowa City, Iowa, United States
  • Minneapolis, Minnesota, United States
  • New York, New York, United States
  • Cincinnati, Ohio, United States
  • Fairfax, Virginia, United States
  • Parkville, Victoria, Australia
  • Calgary, Alberta, Canada
  • Würzburg, Germany
  • Cambridge, United Kingdom
  • London, United Kingdom